Business Context and Reporting Period
This Form 8-K reports on events occurring at the 2022 Annual Meeting of Shareholders held by Processa Pharmaceuticals, Inc. on July 11, 2022. The filing covers corporate governance actions, including director elections, executive compensation votes, and amendments to equity incentive plans.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Corporate Actions
- Incentive Plan Amendment: Shareholders approved an amendment to the 2019 Omnibus Incentive Plan, increasing the authorized share pool by 3,000,000 shares. The total authorized shares under the plan are now 6,000,000.
- Board Composition: Dr. Khalid Islam retired from the Board of Directors effective as of the Annual Meeting.
- Director Elections: Five directors were elected to serve until the next Annual Meeting. All nominees received majority support, though Virgil Thompson received a notable number of "Against" votes (139,021) compared to other nominees.
- Executive Compensation: The advisory vote on executive compensation passed with 8,005,002.5 shares "For" and 7,360 shares "Against."
- Auditor Ratification: Shareholders ratified the appointment of BD & Company, Inc. as the independent registered public accounting firm for 2022.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, or specific risk factors. The document focuses strictly on the results of shareholder votes and the departure of a director.
Investor Verification Checklist
- Verify the impact of the 3,000,000 share increase on potential future dilution for existing shareholders.
- Review the 2022 Proxy Statement (filed May 31, 2022) for the full text of the amended Incentive Plan and details on the retiring director.
- Monitor the voting results for Virgil Thompson, who received significantly more "Against" votes than other directors, to assess potential governance concerns.
- Confirm the transition of audit responsibilities to BD & Company, Inc. for the 2022 fiscal year.